共 208 条
[1]
Fitzmaurice C(2017)Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015 JAMA Oncol 3 524-548
[2]
Allen C(2015) A systematic analysis for the global burden of disease study CA Cancer J Clin 65 87-108
[3]
Barber RM(2003)Global cancer statistics, 2012 J Urol 169 517-523
[4]
Barregard L(2012)Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer Adv Urol 2012 921674-89S
[5]
Bhutta ZA(2016)Review of salvage therapy for biochemically recurrent prostate cancer: the role of imaging and rationale for systemic salvage targeted anti-prostate-specific membrane antigen radioimmunotherapy J Nucl Med 57 79S-796
[6]
Brenner H(2014)The rise of PSMA ligands for diagnosis and therapy of prostate cancer Pharmaceuticals (Basel) 7 779-787
[7]
Dicker DJ(2017)Novel preclinical and radiopharmaceutical aspects of [68Ga]Ga-PSMA-HBED-CC: a new PET tracer for imaging of prostate cancer Eur J Nucl Med Mol Imaging 44 776-458
[8]
Chimed-Orchir O(2010)Local recurrence of prostate cancer after radical prostatectomy is at risk to be missed in 68Ga-PSMA-11-PET of PET/CT and PET/MRI: comparison with mpMRI integrated in simultaneous PET/MRI AJR Am J Roentgenol 194 453-418
[9]
Dandona R(2016)Urography: upper tract opacification and performance for upper tract tumors in patients with hematuria Semin Nucl Med 46 405-209
[10]
Torre LA(2015)Current status of prostate-specific membrane antigen targeting in nuclear medicine: clinical translation of chelator containing prostate-specific membrane antigen ligands into diagnostics and therapy for prostate cancer Eur J Nucl Med Mol Imaging 42 197-937